Home > Insider Trading > Filing (0001127602-10-007954)

Filing Details

Accession Number:: 0001127602-10-007954
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-08 12:00:00
Reporting Period:: 2010-03-04

Filing Date:: 2010-03-08
Accepted Time:: 2010-03-08 18:06:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1097264	Allos Therapeutics Inc	ALTH	Pharmaceutical Preparations (2834)	541655029

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1290061	C David Clark	11080 Circlepoint Road Suite 200 Westminster CO 80020	Vp, Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-03-04	8,333	$2.70	30,413	No	4	M	Direct
Common Stock	Acquisiton	2010-03-04	582	$2.93	30,995	No	4	M	Direct
Common Stock	Disposition	2010-03-04	11,640	$6.98	19,355	No	4	S	Direct
Common Stock	Acquisiton	2010-03-05	10,000	$2.93	29,355	No	4	M	Direct
Common Stock	Disposition	2010-03-05	10,000	$7.02	19,355	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2010-03-04	8,333	$0.00	8,333	$2.70
Common Stock	Stock Options (Right to Buy)	Disposition	2010-03-04	582	$0.00	582	$2.93
Common Stock	Stock Options (Right to Buy)	Disposition	2010-03-05	10,000	$0.00	10,000	$2.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
834	2007-02-10	2016-02-10	No	4	M	Direct
12,251	2007-05-09	2016-05-09	No	4	M	Direct
2,251	2007-05-09	2016-05-09	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan under which Mr. Clark sold a portion of his holdings for tax and estate planning purposes.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $6.87 to $7.01. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $7.00 to $7.05. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
Stock options vest according to the following schedule: One fourth (1/4) of the total number of shares subject to this option shall vest 12 months after the date of grant and an additional one forty-eighths (1/48) of the total number of shares subject to the option shall vest each one month period thereafter, until all such shares are vested and exercisable.
Stock options vest according to the following schedule: One fourth (1/4) of the total number of shares subject to this option shall vest 12 months after the vesting commencement date and an additional one-forty-eigths (1/48) of the total number of shares subject to the option become exercisable each one-month-period thereafter, until all such shares are exercisable.